DIMENSIONAL FUND ADVISORS LP - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
DIMENSIONAL FUND ADVISORS LP ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$15,701,368
-45.3%
941,274
-9.4%
0.01%
-44.4%
Q2 2023$28,700,427
-1.1%
1,039,105
-17.7%
0.01%
-10.0%
Q1 2023$29,031,181
+246910.8%
1,262,259
+17.2%
0.01%
+233.3%
Q4 2022$11,753
-99.8%
1,077,226
+31.3%
0.00%0.0%
Q3 2022$6,916,000
+2.5%
820,438
-3.8%
0.00%
+50.0%
Q2 2022$6,745,000
-67.0%
852,775
-1.2%
0.00%
-66.7%
Q1 2022$20,434,000
-31.7%
862,892
-1.3%
0.01%
-33.3%
Q4 2021$29,913,000
+92.8%
874,651
-0.1%
0.01%
+80.0%
Q3 2021$15,518,000
-56.3%
875,732
+10.7%
0.01%
-54.5%
Q2 2021$35,499,000
+109.1%
791,016
+20.6%
0.01%
+83.3%
Q1 2021$16,979,000
+29.7%
656,101
+1.0%
0.01%
+20.0%
Q4 2020$13,095,000
-2.3%
649,540
-5.2%
0.01%
-16.7%
Q3 2020$13,397,000
+10.4%
685,256
-0.2%
0.01%
+20.0%
Q2 2020$12,130,000
+155.0%
686,897
+2.0%
0.01%
+150.0%
Q1 2020$4,756,000
+0.6%
673,648
+0.4%
0.00%0.0%
Q4 2019$4,729,000
-46.2%
670,751
-8.3%
0.00%
-33.3%
Q3 2019$8,784,000
-2.5%
731,305
-1.7%
0.00%0.0%
Q2 2019$9,010,000
+8.0%
744,058
+12.1%
0.00%0.0%
Q1 2019$8,343,000
+152.9%
663,777
+35.4%
0.00%
+200.0%
Q4 2018$3,299,000
-12.9%
490,267
+33.2%
0.00%0.0%
Q3 2018$3,787,000
+147.4%
368,017
+61.5%
0.00%0.0%
Q2 2018$1,531,000227,8170.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$56,331,20918.32%
Kynam Capital Management, LP 1,375,000$31,625,0004.08%
BVF INC/IL 3,775,900$86,845,7003.18%
Cormorant Asset Management, LP 1,700,000$39,1002.58%
RTW INVESTMENTS, LP 4,600,799$105,818,3772.20%
Ghost Tree Capital, LLC 225,000$5,175,0001.53%
683 Capital Management, LLC 791,000$18,193,0001.36%
Ikarian Capital, LLC 211,400$4,862,2001.10%
Ikarian Capital, LLC 211,400$4,862,2001.10%
SILVERARC CAPITAL MANAGEMENT, LLC 105,486$2,426,1781.00%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders